Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Novo Nordisk Limited .
Filed returns
15
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Sep–Dec 2025 | Novo Nordisk Limited | Health | Proposed Changes to the General Pharmaceutical Legislation (Legislation) | 1 | On lobbying.ie |
| May–Aug 2025 | Novo Nordisk Limited | Health | Engagement with Government regarding the life-sciences sector in Ireland and the EU General Pharmaceutical Legislation (GPL). (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Novo Nordisk Limited | Health | Engagement with Government, MEPs and public officials regarding the life-sciences sector in Ireland and the EU General Pharmaceutical Legislation (GPL) including two roundtable events. (Public policy or programme) | 12 | On lobbying.ie |
| Sep–Dec 2024 | Novo Nordisk Limited | Health | Engagement with Government regarding the life-sciences sector in Ireland and the EU General Pharmaceutical Legislation (GPL). (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2024 | Novo Nordisk Limited | Health | Engagement organised by Novo Nordisk Ireland and IDA Ireland with local Westmeath TD and Minister, Peter Burke, following the acquisition of a manufacturing facility in Athlone. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2024 | Novo Nordisk Limited | Health | Launch of Novo Nordisk Cycle to School initiative, and discussion with Minister of State Jack Chambers regarding the promotion of European competitiveness and the adoption of a life science strategy in Ireland. (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2023 | Novo Nordisk Limited | Health | Launch of Novo Nordisk electric delivery van, and briefing for Minister of State Ossian Smyth regarding Novo Nordisk sustainability initiatives and the importance of an innovative life science ecosystem in Ireland. (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2023 | Novo Nordisk Limited | Health | To discuss the importance of an innovative life science ecosystem in Ireland, outlining Novo Nordisk position on the revision of the EU General Pharmaceutical Legislation. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2023 | Novo Nordisk Limited | Health | Discussions on how Novo Nordisk is managing the green transition and the policy environment for Europe's life-sciences sector. MEP Kelly participated in a European Parliament ITRE (industry) committee delegation to… (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2023 | Novo Nordisk Limited | Health | Attendance at a Vulcan roundtable discussion with MEPs regarding the future of the pharmaceutical industry in Europe. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2023 | Novo Nordisk Limited | Health | To discuss the importance of an innovative life science ecosystem in Ireland, outlining Novo Nordisk position on the revision of the EU General Pharmaceutical Legislation. (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2023 | Novo Nordisk Limited | Health | To discuss the importance of an innovative life science ecosystem in Ireland, outlining Novo Nordisk position on the revision of the EU General Pharmaceutical Legislation. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Novo Nordisk Limited | Health | To discuss the importance of an innovative life science ecosystem in Ireland, outlining Novo Nordisk position on the revision of the EU General Pharmaceutical Legislation. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Novo Nordisk Limited | Health | To discuss the importance of an innovative life science ecosystem in Ireland, outlining Novo Nordisk position on the revision of the EU General Pharmaceutical Legislation. (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2022 | Novo Nordisk Limited | Health | To discuss the importance of an innovative ecosystem, including access and reimbursement environment, for a successful life science industry in Ireland to secure our place as a leading life sciences nation for the… (Public policy or programme) | 3 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 15 | 100.0% |